12:00 AM
Apr 05, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RDEA594: Preliminary Phase IIb data

Preliminary data from a double-blind, international Phase IIb trial in 123 patients showed that 400 and 600 mg daily RDEA594 met the primary endpoint of significantly increasing the proportion of patients who achieved a target serum urate level of <6 mg/dL after 4 weeks vs. placebo (28%...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >